The Pharmaletter

One To Watch

forge_company

Forge Therapeutics

"At Forge Therapeutics, we are developing novel antibiotics targeting bacterial metal-dependent enzymes."

"Forge has a strategic antibiotic discovery relationship with Evotec AG, antibiotic research collaborations with Basilea Pharmaceutica International Ltd. and Hoffmann-La Roche Ltd., and has been awarded funding by CARB-X as well as government agencies. For further information, please visit the company’s website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera."

Want to Update your Company's Profile?


More Forge Therapeutics news >